← Back to headlines
ImmunityBio Clinical Trial for Lymphoma Drug Follows $505M Convertible Note Change
ImmunityBio is conducting a clinical trial for a lymphoma drug, following a significant $505 million convertible note change.
19 Feb, 00:38 — 19 Feb, 00:38
Sources
Showing 1 of 1 sources
Related Stories
Cornerstone Funds Declare Monthly Dividends and Announce 2026/2027 Distributions
3h ago
The OLB Group Reports Q2 Financials; FinVolution Group to Announce Results
5h ago
Mark Cuban and Tech Founders Oppose California Wealth Tax Proposal
7h ago
Greece to Save €2 Billion by Early Debt Repayment in 2026
8h ago